09/02/2026
https://youtu.be/kO2OETQnC5s - VIDEO. Prevention with PURPOSE: An Update on Long Acting Lenacapavir for HIV PrEP. Moupali Das, MD, MPH. Vice President of Clinical Development, HIV Prevention and Virology Pediatrics. Gilead Sciences.
Moupali Das, MD, MPH, is Vice President, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences. She is an Infectious Diseases/HIV trained physician with background in academic medicine and public health. Since joining Gilead Sciences, she has leveraged her clinical HIV and ID expertise, clinical trial design and epidemiology skills, and passion for coaching and mentoring to build and lead high-performing cross-functional teams in HIV treatment and accountable for the overall development strategy and the conception, design and ex*****on of HIV prevention clinical trials from Phase 1 through Phase 4. She oversees the pediatrics team who are deeply committed to ensuring the development of pediatric formulations for Gilead’s virology medications. She is dedicated to ensuring efficient clinical development and global regulatory approvals to support rapid access to innovative products to help end the HIV epidemic for all. She oversees the pediatrics team who are deeply committed to ensuring the development of pediatric formulations for all Gilead’s virology medications.
Moupali has committed her entire educational and professional career to HIV. After completing her A.B. in Biochemical Sciences at Harvard College, medical school and internal medicine residency training at Columbia University and New York Presbyterian Hospital, she came to University of California, San Francisco (UCSF) for fellowship training in Infectious Diseases, HIV prevention fellowship (is a proud CAPS alumna), and to University of California, Berkeley for her MPH in Epidemiology.
Moupali is a stalwart champion accelerating access to innovative products, such as spearheading adding the adolescent indication to Truvada for PrEP and evaluating remdesivir compassionate use in children and pregnant women. For the past approximately five years, Moupali has led the PURPOSE program and HIV Prevention Clinical Development with passion and empathy, revolutionizing how we develop drugs, innovating in the science and health equity, and laying the groundwork for global access.
Moupali received the 2025 Mani L. Bhaumik Breakthrough of the Year Prize on behalf of Gilead Sciences team members working on lenacapavir, along with scientist Wes Sundquist and global advocate, Yvette Raphael.
https://www.science.org/doi/10.1126/science.adz2598
https://www.newyorker.com/news/the-lede/the-drug-that-could-revolutionize-the-fight-against-hiv
This presentation is hosted by CAPS/DPS Town Hall and the CAPS Developmental Core.
Town Hall Co-Chairs: Parya Saberi, PharmD and John Sauceda, PhD, MSc, CAPS Dev Core Co-Directors
